TREMFYA® (guselkumab) demonstrated sustained clinical and endoscopic remission through 3 years in moderately to severely active Crohn's disease
Key Highlights
- ➤TREMFYA 100 mg q8w achieved 94% clinical remission at Week 144
- ➤TREMFYA 200 mg q4w achieved 61% endoscopic remission at Week 144
- ➤88% achieved 90-day corticosteroid-free clinical remission under both regimens
- ➤74% of TREMFYA-treated patients remained on treatment through three years
- ➤Safety findings remained consistent with TREMFYA’s established Crohn’s disease profile
Expert Statements
David Rubin, Director of the Inflammatory Bowel Disease Center at the University of Chicago
“In a chronic, lifelong disease, the ability to sustain clinical and endoscopic outcomes through three years is particularly meaningful for patients”
David Rubin, Director of the Inflammatory Bowel Disease Center at the University of Chicago
“These results contribute to the growing body of evidence that TREMFYA can provide patients with deep and sustained remission over time, creating a strong foundation for long-term disease management.”
David M. Lee, Global Immunology Therapeutic Area Head, Johnson & Johnson
“Johnson & Johnson has built deep expertise in immune-mediated diseases including inflammatory bowel disease, and our research is designed to answer questions that arise over the course of this chronic condition”
David M. Lee, Global Immunology Therapeutic Area Head, Johnson & Johnson
“The clinical and endoscopic remission observed with TREMFYA through three years reinforces our commitment to generating long-term evidence that can help physicians make informed treatment decisions for people living with Crohn's disease.”
TREMFYA® (guselkumab) demonstrated sustained clinical and endoscopic remission through 3 years in moderately to severely active Crohn's disease PR Newswire
* New long-term data showed clinical remission rates of up to 94% and endoscopic remission rates of up to 61% in adults with moderately to severely active Crohn's disease * 88% of patients achieved 90-day corticosteroid-free clinical remission SPRING HOUSE, Pa., Oct. 12, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced new three-year data from the Phase 3 GALAXI 2 and 3 studies showing durable efficacy and a consistent safety profile for TREMFYA(®) (guselkumab) in adults with moderately to severely active Crohn's disease.(1) The Week 144 long-term extension (LTE) results being presented at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting reveal long-term clinical and endoscopic outcomes across both TREMFYA maintenance regimens in this chronic disease.
Get started
Create a free account to read the full story.